Clinical trials: Newly Diagnosed Glioblastoma
MGMT-unmethylated Glioblastoma (GBM), IDH Wildtype Glioblastoma
Safety and Feasibility of First-line Avutometinib and Defactinib in Patients With Newly Diagnosed High-grade Gliomas
This clinical trial is designed with two treatment stages: Stage 1: one cycle of study drug treatment prior to initiation of first-line standard radiation in all study participants.
- Trial name
- NCT07778602
- Testing
- avutometinib and defactinib for 3 weeks on/1 week off, MGMT-unmethylated GBM with Radiation
- Where
- 3 sites in United States, Puerto Rico
- Volunteers
- 22 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Glioblastoma
Trial of Hypofractionated Radiation Therapy for Glioblastoma
This study is being done to compare standard radiation therapy with hypofractionated radiation therapy for patients with newly diagnosed glioblastoma
- Trial name
- NCT02206230
- Testing
- Hypofractionated radiation therapy, Standard radiation therapy
- Where
- Canada
- Volunteers
- 133 people
- Sponsor
- AHS Cancer Control Alberta
Glioblastoma, Glioma, Malignant
Monocyte Antigen Carrier Cells for Newly Diagnosed GBM
The primary purpose of this study is to determine the maximum tolerated dose (MTD) of MT-201-GBM (pp65CMV antigen monocytes) that will be administered to patients newly diagnosed with a type of brain tumor called glioblastoma…
- Trial name
- DEMAND (NCT04741984)
- Testing
- MT-201-GBM monocyte vaccine
- Sponsor
- Michael Gunn
Glioblastoma
Efficiency of Vaccination with Lysate-loaded Dendritic Cells in Patients with Newly Diagnosed Glioblastoma
The primary objective of the study is to determine whether overall survival of newly diagnosed glioblastoma patients treated with lysate-loaded, mature dendritic cell vaccines as add-on to the standard of care consisting of…
- Trial name
- GlioVax (NCT03395587)
- Testing
- Autologous, tumor lysate-loaded, mature dendritic cells (DC), standard therapy
- Where
- 6 sites in Germany
- Volunteers
- 136 people
- Sponsor
- Heinrich-Heine University, Duesseldorf
Glioblastoma
Feasibility Study on LITT for Newly Diagnosed Glioblastoma
Multicenter, open-label, prospective designed study to characterize the performance of brain laser interstitial thermal therapy (LITT) ablation using the Monteris NeuroBlate System in combination with standard of care radiation…
- Trial name
- FLAG (NCT02880410)
- Testing
- NeuroBlate System, Radiation therapy and temozolomide
- Where
- 4 sites in United States
- Volunteers
- 3 people
- Sponsor
- Monteris Medical
Glioblastoma
Paxalisib With a High Fat, Low Carb Diet and Metformin for Glioblastoma
This study is for patients with newly diagnosed glioblastoma, as well as patients who have recurring glioblastoma. Subjects will be given daily paxalisib and metformin while also maintaining a ketogenic diet.
- Trial name
- NCT05183204
- Testing
- Paxalisib, Metformin, Ketogenic Diet
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Weill Medical College of Cornell University
Newly Diagnosed Glioblastoma, MGMT-Unmethylated Glioblastoma
A Single-Arm, Open-Label, Multicenter Clinical Study of Teniposide Combined With Temozolomide for the Treatment of Newly Diagnosed Glioblastoma (nGBM) With MGMT Promotor Region Unmethylated
The Primary Objective of this study is to evaluate the efficacy and safety of teniposide in combination with temozolomide for the treatment of newly diagnosed glioblastoma (nGBM) with MGMT promotor region unmethylated.
- Trial name
- NCT07894549
- Testing
- Teniposide Combined with Temozolomide
- Volunteers
- 72 people
- Sponsor
- Sun Yat-sen University
Brain and Central Nervous System Tumors
ABT-888, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
RATIONALE: ABT-888 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high-energy x-rays to kill tumor cells.
- Trial name
- NCT00770471
- Testing
- temozolomide, veliparib, DNA methylation analysis
- Where
- 11 sites in United States
- Volunteers
- 24 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Glioblastoma Multiforme, Glioblastoma
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
The primary purpose of the study is to determine the efficacy of an investigational therapy called DCVax(R)-L in patients with newly diagnosed GBM for whom surgery is indicated.
- Conditions
- Glioblastoma Multiforme, Glioblastoma, GBM, Grade IV Astrocytoma
- Trial name
- GBM (NCT00045968)
- Testing
- Dendritic cell immunotherapy
- Where
- 86 sites in United States, Canada and 2 more
- Volunteers
- 348 people
- Sponsor
- Northwest Biotherapeutics
Glioblastoma
Standard Temodal (Temozolomide) Regimen Versus Standard Regimen Plus Early Postsurgery Temodal for Newly Diagnosed Glioblastoma Multiforme (Study P05572)
The primary purpose of the study is to evaluate the efficacy and safety of early postsurgery temozolomide chemotherapy followed by the standard temozolomide regimen, compared to the standard regimen alone, for the treatment of…
- Trial name
- NCT00686725
- Testing
- Temozolomide, Radiotherapy
- Volunteers
- 99 people
- Sponsor
- Merck Sharp & Dohme LLC
Brain and Central Nervous System Tumors
Perfusion Magnetic Resonance Imaging in Measuring the Growth of Blood Vessels in Newly Diagnosed Brain Tumors
RATIONALE: Perfusion magnetic resonance imaging may be an effective method of measuring the growth of blood vessels in brain tumors. These measurements may help doctors better diagnose and treat brain tumors.
- Trial name
- NCT00005790
- Testing
- laboratory biomarker analysis, biopsy, magnetic resonance imaging
- Sponsor
- Northwestern University
Glioblastoma
CART-EGFRvIII + Pembrolizumab in GBM
This is an open-label, phase 1 study to assess the safety and tolerability of EGFRvIII T cells in combination with pembrolizumab (PD-1 Inhibitor) in patients with newly diagnosed, EGFRvIII+, MGMT-unmethylated glioblastoma.
- Trial name
- NCT03726515
- Testing
- CART-EGFRvIII T cells, Pembrolizumab
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of Pennsylvania
Glioblastomas, Gliosarcoma
Hyperbaric Hyperoxygenation With Radiotherapy and Temozolomide in Adults With Newly Diagnosed Glioblastoma
Standard treatment for glioblastomas includes radiation and chemotherapy with a drug called temozolomide (Temodar); however, glioblastomas frequently develop resistance to standard treatment and recur or progress.
- Trial name
- HBO (NCT00936052)
- Testing
- Hyperbaric Oxygen Therapy
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Neurological Surgery, P.C.
Glioblastoma Multiforme
A Study of ICT-107 Immunotherapy in Glioblastoma Multiforme (GBM)
This is a phase 2, multicenter study to determine the safety and efficacy of ICT-107 in treating a type of brain tumor called Glioblastoma Multiforme (GBM).
- Trial name
- NCT01280552
- Testing
- ICT-107
- Where
- 25 sites in United States
- Volunteers
- 124 people
- Sponsor
- Precision Life Sciences Group
Newly Diagnosed Glioblastoma, IDH-wildtype
Tris-CAR-T Cell Therapy Targeting CD44 and CD133 in Newly Diagnosed Glioblastoma
This is an investigator-initiated, randomized, open-label, parallel-controlled clinical study designed to evaluate the efficacy and safety of locally administered Tris-CAR-T cells in adults with newly diagnosed glioblastoma.
- Trial name
- CAR-T (NCT07873996)
- Testing
- Tris-CAR-T cell injection, Ommaya reservoir implantation, Temozolomide (TMZ)
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Beijing Tiantan Hospital
Glioblastoma
Imaging Trial With I-124-CLR1404 in Patients With Newly Diagnosed or Recurrent Glioblastoma
The primary objective of this trial is to determine the optimal dose and imaging time point(s) of I-124-CLR1404 in subjects with newly diagnosed and recurrent glioma to be used in future trials.
- Trial name
- NCT01898273
- Testing
- I-124-CLR1404
- Where
- 9 sites in United States
- Volunteers
- 7 people
- Sponsor
- Cellectar Biosciences, Inc.
Glioblastoma
Combining Radiotherapy and Temozolomide With Dichloroacetate in Patients With Newly Diagnosed Glioblastoma
This is a study to see whether radiotherapy plus chemotherapy (Temozolomide) plus Dichloroacetate (DCA) improves overall survival and offers better control of the disease in patients with newly diagnosed Glioblastoma Multiforme…
- Trial name
- NCT00703859
- Testing
- Dichloroacetate (DCA)
- Sponsor
- AHS Cancer Control Alberta
Newly Diagnosed Glioblastoma Who Underwent at Least Partial Resection of the Tumor Surgically
Potentiation of Chemotherapy in Brain Tumors by Zinc
Glioblastoma (GB) is the most common and aggressive type of primary malignant brain tumor in adults. Despite advances in surgical resection, radiotherapy and chemotherapy, prognosis remains very poor.
- Trial name
- NCT04488783
- Testing
- zinc and ascorbate
- Where
- Israel
- Volunteers
- 30 people
- Sponsor
- Sheba Medical Center
Glioblastoma Multiforme, Anaplastic Astrocytoma
Super-Selective Intraarterial Cerebral Infusion Of Temozolomide (Temodar) For Treatment Of Newly Diagnosed GBM And AA
The high-grade malignant brain tumors, glioblastoma multiforme (GBM) and anaplastic astrocytoma (AA), comprise the majority of all primary brain tumors in adults.
- Trial name
- NCT01180816
- Testing
- Super-Selective Intraarterial Intracranial Infusion of Temozolomide
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Northwell Health
MGMT-Unmethylated Glioblastoma
Study of AK105 With Anlotinib and Radiotherapy Adjuvant Therapy in MGMT Unmethylated Newly Diagnosed Glioblastoma.
This is a prospective, open-label single-arm, exploratory, two-stage design trial, aiming to investigate safety and efficacy of AK105 with anlotinib and radiotherapy adjuvant therapy in MGMT unmethylated newly diagnosed…
- Trial name
- NCT05033587
- Testing
- Anlotinib, AK105, Radiotherapy
- Where
- China
- Volunteers
- 28 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School